Biosimilars Hospitals Licensing Therapies 
Drug Discovery World
MARCH 29, 2023
All in all, this is a 10-year period, which the commission seeks to shorten. What of the increased possibilities for ‘replacement pharmacy compounding’ for weekly hospital supplies, and for routine manufacturing of cell and gene therapies without a marketing authorisation? You can compare timelines.
The Pharma Data
AUGUST 3, 2021
Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). AMGEVITA continued to be the most prescribed adalimumab biosimilar in Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 9, 2023
Thereafter, there will be two presentations, which are: Jan Terje Andersen, PhD, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital, on: ‘Biology-based engineering of versatile antibody and albumin technologies’.
The Pharma Data
AUGUST 3, 2021
The EUA now provides for the use of baricitinib for the treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The company and Pfizer Inc. Revenue outside the U.S. million.
The Pharma Data
OCTOBER 29, 2020
. “Our foundation for the future is stronger than ever, and by maintaining our focus on serving patients and delivering for shareholders, I am confident that we will continue to build on our success to date and further advance our mission of delivering life-changing therapies to people with rare diseases and devastating conditions.”
The Pharma Data
NOVEMBER 9, 2020
Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. 6-8 Patients with severe asthma account for twice as many asthma-related hospitalizations. Amgen Inflammation Amgen brings therapies to millions of people with inflammatory diseases, with a focus on serving unmet patient needs.
The Pharma Data
FEBRUARY 8, 2021
At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. price, patients switching to Toujeo ® and biosimilar glargine competition.
Expert insights. Personalized for you.
130 
Let's personalize your content